ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 2568 • ACR Convergence 2023

    First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients

    Michael Chen-Xu1, Daniel Cooper2, Rainer Döffinger2, Dr Rachel Jones3 and Rona Smith2, 1Unviersity of Cambridge, Cambridge, United Kingdom, 2University of Cambridge, Cambridge, United Kingdom, 3Addenbrooke's Hospital, Cambridge, United Kingdom

    Background/Purpose: Primary systemic vasculitis (PSV) patients on immunosuppression are at higher risk of adverse outcomes following COVID-19 infection and often mount suboptimal vaccine responses to…
  • Abstract Number: 0203 • ACR Convergence 2023

    Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization

    Zachary Wallace1, Aaron Wu2, Shruthi Srivatsan2, Naomi Patel2, Jeffrey Sparks3, Eli Miloslavsky2, Hyon K. Choi4, Peter Merkel5, John Stone6 and Emily Hyle2, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA, 5University of Pennsylvania, Philadelphia, PA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA

    Background/Purpose: Rituximab (RTX) is effective for maintaining remission in ANCA-associated vasculitis (AAV) but increases risks for vaccine-preventable severe infections and reduces the immune response to…
  • Abstract Number: 0699 • ACR Convergence 2023

    T Cell Subset Analysis in Patients with Large-Vessel Vasculitis

    Rebecca Kuan1, Christopher Redmond1, McKella Sylvester2, Mary Maclean1, Francoise Meylan1, Marcela Ferrada1, Kaitlin Quinn1 and Peter Grayson3, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2Colgate University, Bethesda, MD, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD

    Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…
  • Abstract Number: 0801 • ACR Convergence 2023

    LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease

    Zhimian Wang, Xin Yu, Hua Chen and Wenjie Zheng, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: Dysregulated Th17 cells are implicated in Behçet's disease (BD). However, the underlying mechanism remains unclear. Here we aim to elucidate the mechanism of forkhead…
  • Abstract Number: 1542 • ACR Convergence 2023

    The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study

    Zachary Wallace1, Xiaoqing Fu2, Shruthi Srivatsan2, Zachary Williams2, Claire Cook2, Jennifer Hanberg2, John Stone3, Hyon K. Choi4 and Yuqing Zhang5, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA, 5Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA

    Background/Purpose: With improvements in the risks of relapse and mortality in ANCA-associated vasculitis (AAV), a better understanding of disease- and treatment-related complications is necessary to…
  • Abstract Number: 1626 • ACR Convergence 2023

    Clinical Presentation, Disease Course and 12-month Outcomes in Childhood Polyarteritis Nodosa: A PedVas Study

    Shamma Alzaabi1, Else Bosman1, David Cabral2, Kimberly Morishita1 and PedVas Investigators Network3, 1Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, BC, Canada, 2BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 3Pediatric Rheumatology, British Columbia Children Hospital, Vancouver, Canada, Vancouver, BC, Canada

    Background/Purpose: Childhood polyarteritis nodosa (PAN) is a systemic vasculitis with necrotizing inflammation that typically affects small and medium-sized arteries. The clinical presentation is variable; it…
  • Abstract Number: 2390 • ACR Convergence 2023

    Characterization of Senescent Cells in Temporal Arteries of Patients with Giant Cell Arteritis Reveal an Inflammatory Phenotype and Strong Dependence from IL-6

    Dimitrios Veroutis1, Ourania D Argryropouou1, Andreas Goules2, Konstantinos Kambas3, Dimitris Anastasios Palamidas1, Konstantinos Evangelou1, Sophia Havaki1, Aikaterini Polyzou1, Evangelia Xingi3, Elli Karatza4, Kyriaki Boki5, alberto cavazza6, Christos Kittas1, Dimitris Thanos7, caterina Ricordi6, chiara marvisi6, Francesco Muratore8, Elena Galli6, Stefania Croci6, Carlo Salvarani9, Vassilis G Gorgoulis1 and Athanasios Tzioufas2, 1National and Kapodistrian University of Athens, Athens, Greece, 2Dept. of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, 3Hellenic Pasteur Institute, Athens, Greece, 4Laikon General Hospital, Athens, Greece, 5Sismanoglion Hospital, Athens, Greece, 6Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, 7Biomedical Research Foundation of the Academy of Athens, Athens, Greece, 8IRCCS di Reggio Emilia, Reggio Emilia, Italy, 9Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Age is the strongest risk factor of giant cell arteritis (GCA), implying a possible pathogenetic role of cellular senescence. So far, no studies have…
  • Abstract Number: 2417 • ACR Convergence 2023

    Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study

    LUIGI BOIARDI1, PIERLUIGI MACCHIONI2, Francesco Muratore3, Elena Galli4, chiara marvisi4, caterina Ricordi4, federica Macaluso1, alberto cavazza4, Stefania Croci4 and Carlo Salvarani5, 1IRCCS REGGIO EMILIA, Reggio Emilia, Italy, 2Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, 5Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Few studies have evaluted the influence of histological features of temporal artery biopsy (TAB) on disease outcome in giant cell arteritis (GCA) patients. Our…
  • Abstract Number: 2599 • ACR Convergence 2023

    Study of the Role of interleukin-17 in Giant Cell Arteritis

    helene Greigert1, andre ramon2, corentin Richard3, claudie cladière4, Marion CIUDAD5, catherine creuzot-garcher6, laurent martin7, Sylvain AUDIA1, romain boidot3, Bernard Bonnotte1 and Maxime Samson1, 1Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 2Department of Rheumatology, Dijon University Hospital, Dijon, France, 3Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, 4INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, 5Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Dijon, France, 6Department of Ophthalmology, Dijon University Hospital, Dijon, France, 7Department of Pathology, Dijon University Hospital, Dijon, France

    Background/Purpose: Giant cell arteritis (GCA) is a vasculitis in which Th17 cells have been identified in excess in lesions and in the blood of patients.…
  • Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium

    Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants

    Greta Mastrangelo1, Ellen Go2, Paul Tsoukas2, Hua Lu3, Amy Xu2, Arthur Hoi Hin Cheng2 and Rae Yeung4, 1The Hospital of Sick Children,Department of Paediatrics, University of Toronto, Division of Rheumatology, Toronto, ON, Canada, 2The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada, 4The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…
  • Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium

    Patient Reported Outcomes in Pediatric Vasculitis

    Clare Peckenpaugh1, Aimee Hersh2, CJ Inman1, Sara Stern1, Erin Treemarcki2, Peter Merkel3 and Karen James1, 1University of Utah Department of Pediatrics, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3University of Pennsylvania, Philidelphia, PA

    Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…
  • Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium

    Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?

    Gleice Clemente1, Maria Teresa Terreri2, Bruno Gualano3, Clovis Silva4 and Alexandre Wagner De Souza1, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2UNIFESP, São Paulo, Brazil, 3Universidade de São Paulo, São Paulo, 4Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…
  • Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium

    Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey

    Daniel Ibanez1, Bianca Lang2, Ali Yalcindag3, Linda Wagner-Weiner4, Julia Shalen5, Kenneth Schikler6, Shoghik Akoghlanian7, Hulya Bukulmez8, Kristen Hayward9, Sivia Lapidus10, Andrea Ramirez11, Robert Sundel1, Cagri Yildirim-Toruner12 and CARRA Registry Investigators13, 1Boston Children's Hospital, Boston, MA, 2Dalhousie University - Halifax, Halifax, NS, Canada, 3Hasbro Children's Hospital, Milton, MA, 4The University of Chicago, Chicago, IL, 5Johns Hopkins University, Baltimore, MD, 6University of Louisville School of Medicine Norton Children's Hospital, Louisville, KY, 7Nationwide Children's Hospital, Columbus, OH, 8MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, 9Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA, 10Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, 11Baylor College of Medicine, Houston, TX, 12Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 13CARRA, Washington, DC

    Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…
  • Abstract Number: 071 • 2023 Pediatric Rheumatology Symposium

    Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort

    Ana Luiza Altaffer1, Alvaro Orjuela2 and Marietta De Guzman2, 1Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…
  • Abstract Number: L17 • ACR Convergence 2022

    Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis

    Robert Maughan1, Andrew Porter1, Chanaka Dahanayake2, Claudia Ianonne1, Ritu Alapat1, Charis Pericleous1, Taryn Youngstein3 and Justin Mason1, 1Imperial College London, London, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom, 3Imperial NHS Trust, London, United Kingdom

    Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 41
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology